Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16938118 | 1.00 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL26497469 | 0.84 | CNR2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL25762272 | 0.79 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2338941 | 0.79 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL10308676 | 0.78 | ALDH1A1 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL25762212 | 0.78 | CYP2C19 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL1734717 | 0.77 | — | — | |
| SCHEMBL160033 | 0.77 | — | — | |
| SCHEMBL15352 | 0.77 | — | — | |
| SCHEMBL13256802 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197507-A1 | MALODOR REDUCTION COMPOSITIONS | The Procter and Gamble Company (US) | 2017-08-02 | — | — | EP | claimed |
| WO-2016049389-A1 | MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| CN-109415819-A | For removing the composition of iron sulfide | 株式会社可乐丽 | 2019-03-01 | — | — | CN | disclosed |
| US-9714946-B2 | Bromodomain binding reagents and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160033519-A1 | BROMODOMAIN BINDING REAGENTS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | CHRNB2 1270/4885CHRNB4 2188/4885CHRNA3 1741/4885 |
| US-20160033519-A1 | BROMODOMAIN BINDING REAGENTS AND USES THEREOF | BRD4, BRD1, BRDT | CHRNB2 915/4885CHRNB4 959/4885CHRNA3 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.